Dual targeting smart drug delivery system for multimodal synergistic combination cancer therapy with reduced cardiotoxicity. (1st September 2021)

• Record Type: Journal Article
• Authors: Shubhra, Quazi T.H.; Guo, Kai; Liu, Yixuan; Razzak, Md; Serajum Manir, Md.; Moshiul Alam, A.K.M.
• Is Part Of: Acta biomaterialia. Volume 131(2021)
• Page Start: 493
• Page End: 507
• Publication Date: 2021-09-01
• Subjects: Magnetic photothermal nanoparticles -- Chemo-photothermal-starvation combination therapy -- Cardiotoxicity -- Smart drug delivery system -- Dual targeting -- Cancer; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2021.06.016
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: This study first reports the development of a smart drug delivery system (DDS) for multimodal synergistic cancer therapy combining chemo-photothermal-starvation approaches. A magnetic photothermal agent was synthesized by preparing iron oxide (IO) nanoparticles (NPs) with covalently attached indocyanine green (ICG) and glucose oxidase (GOx) (ICGOx@IO). Synthesized ICGOx@IO NPs were co-encapsulated with doxorubicin (Dox) and EGCG ((-)-epigallocatechin-3-gallate) inside PLGA (poly(lactic-co-glycolic acid)) NPs using multiple emulsion solvent evaporation method. Such formulation gave the advantage of triggered drug release by near-infrared (NIR) laser irradiation (808 nm at 1 W/cm 2 ). RGD peptide was attached to the surface of PLGA NPs and the final hydrodynamic size was around 210 nm. Dual targeting by peptide and 240 mT external magnet significantly improved cellular uptake. Cellular uptake was observed using FACS, electron and optical microscopy. Dual targeting along with laser irradiation could reduce in vitro cell viability by 90 ± 2% (Dox-equivalent dose: 10 µg/ml) and complete tumor ablation was achieved in vivo due to synergetic therapeutic effect. Another attractive feature of the DDS was the significant reduction of cardiotoxicity of doxorubicin by EGCG. This new platform is thus expected to hold strong promise for future multimodal combination therapy of cancers. Statement of significance: Doxorubicin is one of the most studied and effective chemotherapeutic agents whose application is hindered due to its cardiotoxicity. In this study, we used (-)-Epigallocatechin-3-gallate (EGCG) to overcome that limitation. However, drug delivery to tumor sites with no/minimum accumulation in healthy organs is always challenging. Although peptide-based targeting is very popular, the effectiveness of receptor/ligand binding active targeting is sometimes questioned which motivated us to apply dual targeting approach. Multimodal therapies can exhibit synergistic effects and subsequently reduce the required dose of drug over monotherapy. We aimed to achieve chemo-photothermal-starvation combination therapy in this study and such achievement is yet to be reported. Our developed system also has the advantage of triggered drug release by near-infrared (NIR) laser irradiation. Graphical abstract: Image, graphical abstract